非小细胞肺癌(NSCLC)早中期患者以手术为治疗首选,但术后仍有较高复发转移率.近年来预防NSCLC根治术后复发转移的方法多样,术后辅助化疗已成为共识,放疗为术后局部治疗的主要手段,但并非所有N2期患者均能从放疗中获益,靶向治疗仍存在争议,国内外多项研究仍在进行中,中医药可提高免疫力,改善生活质量.尽管如此,预防NSCLC根治术后患者复发转移仍存在许多问题,如超过常规时间接受化疗是否仍可获益、对淋巴结转移数目<4个但存在跳跃式转移患者放疗是否获益、靶向药在术后辅助治疗的地位及具体使用方法、中医药延长无病生存期与TNM分期的相关性等.%Surgery is the preferred treatment in the early metaphase of non-small cell lung cancer(NSCLC),but there is a high probability of recurrence and metastasis after the surgical treatment.Adjuvant chemotherapy has become the com-monly accepted postoperative treatment in recent years.Postoperative radiotherapy is the main method of local treatment,but not all N2patients can benefit from it.Effectiveness of targeted therapy is still controversial and its researches in domestic and foreign fields are still in progress.Even though traditional Chinese medicine can enhance human immunity and improve the quality of life,there are still a number of problems in prevention of recurrence and metastasis after radical resection for NSCLC that need to be solved,such as if it is beneficial for the patients who receive adjuvant chemotherapy exceeding the conventional time,and if it is beneficial for those who receive postoperative radiotherapy with <4 positive nodes but having skipping metastasis,plus other problems such as the status and specific usage of targeted drugs in the postoperative adjuvant treatment and the relevance of prolonging disease free survival by traditional Chinese medicine and TNM stage.
展开▼
